Compare DexCom, Inc. (DXCM) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.92 (market cap $1.45B). The key difference: DexCom, Inc. is far larger — about 22× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days on average.
| DXCM | QQQE | |
|---|---|---|
Market Cap | $31.86B | $1.45B |
Volume | 3,607,070 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $124.69 |
52-Week Low | $54.84 | $96.06 |
Typical Hold Time | 62 Days | 48 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
QQQE trades at $121.92 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with moving averages supporting upward momentum while oscillators remain neutral. The ETF's equal-weighted approach to NASDAQ-100 stocks provides diversification benefits, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers stronger fundamentals and technicals than QQQ for tactical positioning.
The outlook appears favorable with equal weighting providing balanced exposure to large-cap growth stocks. Key risks include technology sector volatility and market concentration concerns. Analyst sentiment leans positive for near-term performance, though investors should monitor broader market trends and sector rotations that could impact the NASDAQ-100 composition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
